On July 30, 2025, Moderna announced that the European Commission (EC) granted marketing authorization for the updated formulation of Moderna’s COVID-19 vaccine Spikevax®. The updated vaccine targets the LP.8.1 variant of...more
8/19/2025
/ Biotechnology ,
Coronavirus/COVID-19 ,
European Commission ,
European Medicines Agency (EMA) ,
Life Sciences ,
Marketing Authorization Application ,
Moderna Inc. ,
Pharmaceutical Industry ,
Prescription Drugs ,
Public Health ,
Vaccinations
On May 27, 2025, Fresenius Kabi (“Fresenius”) announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) had issued positive opinions for Fresenius’s two denosumab biosimilar candidates....more